RT Journal Article
SR Electronic
T1 Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against native-like vaccine and delta variant spike trimers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.01.22270279
DO 10.1101/2022.02.01.22270279
A1 Narayanaiah Cheedarla
A1 Hans P. Verkerke
A1 Sindhu Potlapalli
A1 Kaleb Benjamin McLendon
A1 Anamika Patel
A1 Filipp Frank
A1 Gregory L. Damhorst
A1 Huixia Wu
A1 William Henry O’Sick
A1 Daniel Graciaa
A1 Fuad Hudaib
A1 David N Alter
A1 Jeannette Bryksin
A1 Eric A. Ortlund
A1 Jeanette Guarner
A1 Sara Auld
A1 Sarita Shah
A1 Wilbur Lam
A1 Dawn Mattoon
A1 Joseph M Johnson
A1 David H Wilson
A1 Madhav V. Dhodapkar
A1 Sean R. Stowell
A1 Andrew S. Neish
A1 John D. Roback
YR 2022
UL http://medrxiv.org/content/early/2022/02/02/2022.02.01.22270279.abstract
AB Traditional cellular and live-virus methods for detection of SARS-CoV-2 neutralizing antibodies (nAbs) are labor- and time-intensive, and thus not suited for routine use in the clinical lab to predict vaccine efficacy and natural immune protection. Here, we report the development and validation of a rapid, high throughput method for measuring SARS-CoV-2 nAbs against native-like trimeric spike proteins. This assay uses a blockade of hACE-2 binding (BoAb) approach in an automated digital immunoassay on the Quanterix HD-X platform. BoAb assays using vaccine and delta variant viral strains showed strong correlation with cell-based pseudovirus and live-virus neutralization activity. Importantly, we were able to detect similar patterns of delta variant resistance to neutralization in samples with paired vaccine and delta variant BoAb measurements. Finally, we screened clinical samples from patients with or without evidence of SARS-CoV-2 exposure by a single-dilution screening version of our assays, finding significant nAb activity only in exposed individuals. In principle, these assays offer a rapid, robust, and scalable alternative to time-, skill-, and cost-intensive standard methods for measuring SARS-CoV-2 nAb levels.Competing Interest StatementN.C., H.V., S.P., K.B.M., W.H.Os., H.W., A.S.N., and J.D.R. are co-inventors of BoAb assay technology. Emory University filed a patent on this technology.Funding StatementA.S.N., and J.D.R received grants from NIH/NCI, 1 U54 CA260563-01: Immune regulation of COVID-19 infection in cancer and autoimmunity and Emory CURE grant from Emory University, Atlanta, USAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples were sourced from various studies with IRB 00001663 at Emory University after obtaining the approval and consent from Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript